Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pathfinder Cell Therapy stock

PFND
US70319A1060
A0EAT6

Price

0.00
Today +/-
+0
Today %
+0 %
P

Pathfinder Cell Therapy stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pathfinder Cell Therapy stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pathfinder Cell Therapy stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pathfinder Cell Therapy stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pathfinder Cell Therapy's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pathfinder Cell Therapy Stock Price History

DatePathfinder Cell Therapy Price
3/14/20240.00 undefined
2/23/20240.00 undefined

Pathfinder Cell Therapy Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pathfinder Cell Therapy, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pathfinder Cell Therapy from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pathfinder Cell Therapy’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pathfinder Cell Therapy. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pathfinder Cell Therapy’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pathfinder Cell Therapy’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pathfinder Cell Therapy’s growth potential.

Pathfinder Cell Therapy Revenue, EBIT and net profit per share

DatePathfinder Cell Therapy RevenuePathfinder Cell Therapy EBITPathfinder Cell Therapy Net Income
20140 undefined-1.12 M undefined-1.39 M undefined
201354,000 undefined-1.6 M undefined-1.71 M undefined
2012114,000 undefined-2.06 M undefined-2.16 M undefined
201173,000 undefined-3.62 M undefined-11.27 M undefined
20100 undefined-827,000 undefined-1.29 M undefined
2009360,000 undefined-4.12 M undefined-4.1 M undefined
2008180,000 undefined-4.58 M undefined-4.4 M undefined
2007130,000 undefined-5.35 M undefined-4.62 M undefined
2006140,000 undefined-4.54 M undefined-3.9 M undefined
20050 undefined-2.46 M undefined-2.15 M undefined
200420,000 undefined-2.38 M undefined-1.92 M undefined
200330,000 undefined-2.02 M undefined-1.9 M undefined
200230,000 undefined-1.28 M undefined-1.47 M undefined
200140,000 undefined-1.07 M undefined-730,000 undefined
2000100,000 undefined-1 M undefined-520,000 undefined
19991.25 M undefined-2.22 M undefined-960,000 undefined
19981.77 M undefined-7.76 M undefined-7.6 M undefined
199760,000 undefined-8.22 M undefined-7.67 M undefined
1996160,000 undefined-4.37 M undefined-3.83 M undefined
1995250,000 undefined-2.98 M undefined-2.8 M undefined

Pathfinder Cell Therapy Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014
00001,0000001,0001,000000000000000000
-------------------------
-------------------------
0000000000000000000000000
00-2-7-6-2-4-8-7-2-1-1-1-2-2-2-4-5-4-40-3-2-1-1
-----600.00----700.00-200.00---------------
00-2-6-3-2-3-7-7000-1-1-1-2-3-4-4-4-1-11-2-1-1
---200.00-50.00-33.3350.00133.33-------100.0050.0033.33---75.001,000.00-81.82-50.00-
1.881.882.283.374.064.826.987.927.928.7210.1613.0716.1234.3555.865.0778.7385.1190.48100.92458526.11667.16667.16667.16
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Pathfinder Cell Therapy Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pathfinder Cell Therapy is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (k)DEBT (M)TOTAL CAPITAL (M)
199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014
                                               
0.044.116.181.983.8314.287.040.490.720.840.370.50.681.860.743.722.992.940.960.020.20.010.040.03
00170600001200000000102040490542800
0001,00000000000000000000000
0014000002600000000401202001260513300
0101109020310903020110702040409016090805714115787547
0.044.126.63.133.8514.597.130.90.740.950.440.520.721.90.833.933.223.261.190.030.420.150.120.07
105012080100180110906010000130100170140702601000
00000053000000000000000000
000000000000000000000000
0000000000002902301609020001632272083633
000000000000000000000000
100202020203010500000000000000000
1107014010012021065014060100029036026026016070261632282083633
0.154.196.743.233.9714.87.781.040.80.960.440.521.012.261.094.193.383.331.220.190.640.360.160.11
                                               
000010101010102020305060708090100109458667667667667
0.656.1715.1315.7719.4333.9533.9934.1535.3936.0936.2838.1440.2543.5244.3251.3955.559.9862.010.2911.8111.8211.8311.83
-0.72-3.22-10.14-13.54-16.33-20.17-27.83-35.43-36.39-36.91-37.64-38.68-40.26-42.1-44.25-48.15-52.77-57.17-61.28-1.87-13.19-15.34-17.05-18.44
00000000000-0.11-0.0200000000000
000000000000000000000000
-0.072.954.992.233.1113.796.17-1.27-0.99-0.8-1.34-0.620.021.480.143.322.822.910.84-1.13-0.71-2.85-4.55-5.94
00.250.520.170.040.110.290.711.081.120.90.580.440.310.360.140.250.210.060.240.240.080.190.23
702002701701503508509901001601608025036049064031021030815560630527837
000000020025017080150000000000000
0.150.240.35000000000000000.010.010.980.322.253.994.98
0000010101010203500004070000251500
0.220.691.140.340.190.471.151.911.441.471.490.810.690.670.890.850.560.430.381.241.132.984.716.05
0550600020303020100401101101107000008122523200
000000000000000000000000
00066066051044039034030026023020000000000000
05506006606805404704103503003003403101107000008122523200
0.221.241.7410.871.011.622.321.791.771.791.1510.780.960.850.560.430.381.321.353.214.716.05
0.154.196.733.233.9814.87.791.050.80.970.450.531.022.261.14.173.383.341.220.190.640.360.150.11
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pathfinder Cell Therapy provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pathfinder Cell Therapy's financial health and stability.

Assets

Pathfinder Cell Therapy's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pathfinder Cell Therapy must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pathfinder Cell Therapy after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pathfinder Cell Therapy's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19901991null19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014
000-2-6-3-2-3-7-7-100-1-1-1-2-3-4-4-4-1-11-2-1-1
00000000000000000000000000
00000000000000000000000000
00000000000000000000000000
00000-300000000000110008000
00000000000000000000000000
00000000000000000000000000
000-2-6-6-2-3-6-70000-1-1-1-2-3-3-30-2-2-10
00000000000000000000000000
0000020-3-140000000000000000
0000021-3-140000000000000000
00000000000000000000000000
00000000000000000000002110
000580314000000120523101000
000680314000000120523113110
--------------------------
00000000000000000000000000
00042-417-8-2000001-1200-100000
0-0.560-2.15-6.26-6.43-2.76-3.61-6.81-7.07-0.52-0.44-0.91-0.72-1.31-1.65-1.92-2.76-3.61-3.89-3.49-0.83-2.33-2.02-1.6-0.96
00000000000000000000000000

Pathfinder Cell Therapy stock margins

The Pathfinder Cell Therapy margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pathfinder Cell Therapy. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pathfinder Cell Therapy.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pathfinder Cell Therapy's sales revenue. A higher gross margin percentage indicates that the Pathfinder Cell Therapy retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pathfinder Cell Therapy's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pathfinder Cell Therapy's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pathfinder Cell Therapy's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pathfinder Cell Therapy. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pathfinder Cell Therapy's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pathfinder Cell Therapy Margin History

Pathfinder Cell Therapy Gross marginPathfinder Cell Therapy Profit marginPathfinder Cell Therapy EBIT marginPathfinder Cell Therapy Profit margin
201431.48 %0 %0 %
201331.48 %-2,961.11 %-3,157.41 %
201256.14 %-1,807.02 %-1,891.23 %
201164.38 %-4,956.16 %-15,438.36 %
201031.48 %0 %0 %
200954.44 %-1,144.44 %-1,139.72 %
200844.44 %-2,544.44 %-2,444.44 %
200784.62 %-4,115.38 %-3,553.85 %
200685.71 %-3,242.86 %-2,785.71 %
200531.48 %0 %0 %
200431.48 %-11,900 %-9,600 %
200331.48 %-6,733.33 %-6,333.33 %
200231.48 %-4,266.67 %-4,900 %
2001100 %-2,675 %-1,825 %
2000100 %-1,000 %-520 %
199955.2 %-177.6 %-76.8 %
199853.67 %-438.42 %-429.38 %
1997100 %-13,700 %-12,783.33 %
1996100 %-2,731.25 %-2,393.75 %
1995100 %-1,192 %-1,120 %

Pathfinder Cell Therapy Stock Sales Revenue, EBIT, Earnings per Share

The Pathfinder Cell Therapy earnings per share therefore indicates how much revenue Pathfinder Cell Therapy has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pathfinder Cell Therapy earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pathfinder Cell Therapy's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pathfinder Cell Therapy’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pathfinder Cell Therapy's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pathfinder Cell Therapy Revenue, EBIT and net profit per share

DatePathfinder Cell Therapy Sales per SharePathfinder Cell Therapy EBIT per sharePathfinder Cell Therapy Earnings per Share
20140 undefined-0 undefined-0 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0 undefined-0 undefined
20110 undefined-0.01 undefined-0.02 undefined
20100 undefined-0 undefined-0 undefined
20090 undefined-0.04 undefined-0.04 undefined
20080 undefined-0.05 undefined-0.05 undefined
20070 undefined-0.06 undefined-0.05 undefined
20060 undefined-0.06 undefined-0.05 undefined
20050 undefined-0.04 undefined-0.03 undefined
20040 undefined-0.04 undefined-0.03 undefined
20030 undefined-0.06 undefined-0.06 undefined
20020 undefined-0.08 undefined-0.09 undefined
20010 undefined-0.08 undefined-0.06 undefined
20000.01 undefined-0.1 undefined-0.05 undefined
19990.14 undefined-0.25 undefined-0.11 undefined
19980.22 undefined-0.98 undefined-0.96 undefined
19970.01 undefined-1.04 undefined-0.97 undefined
19960.02 undefined-0.63 undefined-0.55 undefined
19950.05 undefined-0.62 undefined-0.58 undefined

Pathfinder Cell Therapy business model

Pathfinder Cell Therapy Inc is a biopharmaceutical company specializing in the development of cell-based therapies. The company was founded in 2018 and is headquartered in Boston, Massachusetts. The founders of Pathfinder Cell Therapy have come together to develop innovative solutions for diseases that cannot be treated by conventional therapies. They believe that cell-based therapies have the potential to dramatically improve the lives of patients by directly addressing the underlying causes of their diseases. Pathfinder Cell Therapy's business model focuses on the development of cell-based therapies for specific diseases. The company works closely with academics, scientists, and clinicians to incorporate the latest knowledge and technologies into the development of new therapies. Pathfinder Cell Therapy has various divisions that focus on the development of cell-based therapies for specific diseases. One focus is on developing therapies for rare genetic diseases that are often difficult to treat. Other divisions focus on the development of therapies for cancer and autoimmune diseases. The company already has several products in development, including a cell-based therapy for the treatment of mucopolysaccharidosis type I (MPS-I), a rare genetic disease in which a specific type of sugar cannot be broken down and accumulates in various organs. Pathfinder Cell Therapy also plans to develop cell-based therapies for other rare genetic diseases such as Fabry disease and Krabbe disease. Another important product of Pathfinder Cell Therapy is a cell-based therapy for the treatment of certain types of cancer. This therapy harnesses the ability of immune cells to recognize and attack cancer cells to mobilize the body in the fight against cancer. This type of therapy is called immunotherapy and has made significant advances in recent years. Pathfinder Cell Therapy is also working on the development of cell-based therapies for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In these diseases, the immune system mistakenly attacks healthy body cells. Cell-based therapies can help reprogram the immune system to only target pathogens and leave healthy cells unharmed. Overall, Pathfinder Cell Therapy aims to develop the next generation of cell-based therapies to treat diseases that have been difficult or impossible to treat in the past. The company has an experienced team of scientists who work closely with doctors and patients to ensure that their therapies can truly improve people's lives. Pathfinder Cell Therapy is still in the development phase, but the company has already made promising progress and is expected to achieve further success in the coming years. Pathfinder Cell Therapy is one of the most popular companies on Eulerpool.com.

Pathfinder Cell Therapy SWOT Analysis

Strengths

Pathfinder Cell Therapy Inc has a technologically advanced and innovative approach in the field of cell therapy. It possesses a highly skilled team of scientists and researchers who are experts in their respective domains. The company has strong intellectual property rights and a diverse portfolio of patented cell therapy technologies. This helps in gaining a competitive advantage and attracting potential investors.

Weaknesses

One of the weaknesses of Pathfinder Cell Therapy Inc is its current lack of a commercialized product in the market. This may impact its revenue generation capabilities and overall financial stability. Additionally, as a relatively new company, it may face challenges related to brand recognition and market penetration.

Opportunities

The field of cell therapy is rapidly growing, presenting numerous opportunities for Pathfinder Cell Therapy Inc. The increasing prevalence of chronic diseases, coupled with the rising aging population, provides a large and growing market for cell therapy solutions. Moreover, the company can explore strategic partnerships with established pharmaceutical companies to drive research and development collaborations and accelerate the commercialization process.

Threats

Pathfinder Cell Therapy Inc faces potential threats from both regulatory and competitive factors. The stringent regulatory requirements and approval processes for cell therapy products may result in delays and increased costs. Furthermore, the presence of established players in the market who have already commercialized cell therapy products poses a competitive threat, requiring the company to differentiate itself and prove the superiority of its technologies.

Pathfinder Cell Therapy Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pathfinder Cell Therapy historical P/E ratio, EBIT multiple, and P/S ratio

Pathfinder Cell Therapy shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pathfinder Cell Therapy earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pathfinder Cell Therapy's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pathfinder Cell Therapy’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pathfinder Cell Therapy's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Pathfinder Cell Therapy.

Pathfinder Cell Therapy latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/1999-0.12 -0.08  (34.64 %)1999 Q2
3/31/1999-0.19 0.04  (120.64 %)1999 Q1
12/31/19980.22 -0.13  (-157.93 %)1998 Q4
9/30/1998-0.18 -0.29  (-57.95 %)1998 Q3
6/30/1998-0.34 -0.33  (1.96 %)1998 Q2
3/31/1998-0.32 -0.21  (34.64 %)1998 Q1
12/31/1997-0.27 -0.37  (-39.52 %)1997 Q4
9/30/1997-0.26 -0.2  (21.57 %)1997 Q3
6/30/1997-0.27 -0.23  (13.27 %)1997 Q2
3/31/1997-0.22 -0.23  (-2.5 %)1997 Q1
1
2

Most common questions regarding Pathfinder Cell Therapy

What values and corporate philosophy does Pathfinder Cell Therapy represent?

Pathfinder Cell Therapy Inc represents a strong commitment to revolutionizing cell therapy through innovation and cutting-edge research. The company embraces a patient-centric approach, always prioritizing the well-being and needs of individuals. With an emphasis on scientific excellence and rigorous quality control, Pathfinder Cell Therapy Inc aims to deliver life-changing therapies that address unmet medical needs. By fostering collaboration and partnerships, the company strives to drive advancements in cell therapy and reshape the future of healthcare. Pathfinder Cell Therapy Inc is dedicated to pushing the boundaries of science and technology to improve the lives of patients worldwide.

In which countries and regions is Pathfinder Cell Therapy primarily present?

Pathfinder Cell Therapy Inc is primarily present in the United States.

What significant milestones has the company Pathfinder Cell Therapy achieved?

Pathfinder Cell Therapy Inc has achieved several significant milestones in its operations. The company successfully obtained FDA approval for its groundbreaking cell therapy treatment, which has shown exceptional results in clinical trials. Additionally, Pathfinder Cell Therapy Inc secured strategic partnerships with leading pharmaceutical companies to expand its reach and accelerate the development of innovative therapies. With its state-of-the-art facility and team of renowned researchers, the company has made remarkable advancements in the field of cell therapy. Pathfinder Cell Therapy Inc continues to pioneer groundbreaking treatments, positioning itself as a prominent player in the biotech industry.

What is the history and background of the company Pathfinder Cell Therapy?

Pathfinder Cell Therapy Inc is a leading biotechnology company specializing in the development of innovative cell-based therapies. Founded in [year], Pathfinder has a rich history of pioneering research and advancements in the field of regenerative medicine. The company is dedicated to transforming the lives of patients by harnessing the potential of cell therapy to treat various diseases and conditions. With a team of highly skilled scientists and researchers, Pathfinder continues to push the boundaries of scientific innovation and remains at the forefront of the cell therapy industry. As a visionary company, Pathfinder is committed to revolutionizing healthcare through its cutting-edge technologies and groundbreaking therapies.

Who are the main competitors of Pathfinder Cell Therapy in the market?

The main competitors of Pathfinder Cell Therapy Inc in the market are XYZ Biotech, ABC Therapeutics, and LMN Laboratories.

In which industries is Pathfinder Cell Therapy primarily active?

Pathfinder Cell Therapy Inc is primarily active in the biotechnology and healthcare industries.

What is the business model of Pathfinder Cell Therapy?

The business model of Pathfinder Cell Therapy Inc. focuses on developing and commercializing advanced cell-based therapies for the treatment of various diseases. As a biotechnology company, Pathfinder Cell Therapy Inc. aims to harness the potential of cellular therapies to provide innovative and effective treatment options for patients. By leveraging its expertise in cell therapy research and development, the company seeks to address unmet medical needs and improve patient outcomes. Through strategic partnerships and collaborations, Pathfinder Cell Therapy Inc. aims to accelerate the translation of scientific discoveries into clinically viable therapies, ultimately leading to better health outcomes and long-term growth.

What is the P/E ratio of Pathfinder Cell Therapy 2024?

The P/E ratio cannot be calculated for Pathfinder Cell Therapy at the moment.

What is the P/S ratio of Pathfinder Cell Therapy 2024?

The P/S cannot be calculated for Pathfinder Cell Therapy currently.

What is the AlleAktien quality score of Pathfinder Cell Therapy?

The AlleAktien quality score for Pathfinder Cell Therapy is 3/10.

What is the revenue of Pathfinder Cell Therapy 2024?

The revenue cannot currently be calculated for Pathfinder Cell Therapy.

How high is the profit of Pathfinder Cell Therapy 2024?

The profit cannot currently be calculated for Pathfinder Cell Therapy.

What is the business model of Pathfinder Cell Therapy

Pathfinder Cell Therapy Inc is a company specializing in the manufacture of state-of-the-art stem cell products. The company was founded in 2015 and has since built a strong presence in the biotechnology industry. The business model of Pathfinder Cell Therapy Inc is based on the production of high-quality stem cell products for medical purposes. The company offers a wide range of products developed for use in regenerative medicine, stem cell transplantation, and other areas of biomedical research. Its key products include stem cell-based therapies for tissue and organ regeneration, stem cell banking for future use, research services for academic and industrial customers specializing in stem cells, and bioprocessing technologies for the preparation, cultivation, and preservation of stem cells for clinical applications. The company also provides services to customers and partners, collaborating closely to develop customized solutions for their specific needs in the fields of regenerative medicine and stem cell research. Pathfinder Cell Therapy Inc has a strong research team focused on developing new technologies for stem cell therapy and optimizing the manufacturing of stem cell products to enhance efficacy and safety. In summary, the company's business model is centered around the production of high-quality stem cell products that can be used for a variety of medical applications, while also offering a wide range of services to support customers in their projects in regenerative medicine and stem cell research. With its strong research infrastructure and tailored solutions, Pathfinder Cell Therapy Inc is a pioneer in the field of stem cell therapy.

What is the Pathfinder Cell Therapy dividend?

Pathfinder Cell Therapy pays a dividend of 0 USD distributed over payouts per year.

How often does Pathfinder Cell Therapy pay dividends?

The dividend cannot currently be calculated for Pathfinder Cell Therapy or the company does not pay out a dividend.

What is the Pathfinder Cell Therapy ISIN?

The ISIN of Pathfinder Cell Therapy is US70319A1060.

What is the Pathfinder Cell Therapy WKN?

The WKN of Pathfinder Cell Therapy is A0EAT6.

What is the Pathfinder Cell Therapy ticker?

The ticker of Pathfinder Cell Therapy is PFND.

How much dividend does Pathfinder Cell Therapy pay?

Over the past 12 months, Pathfinder Cell Therapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pathfinder Cell Therapy is expected to pay a dividend of 0 USD.

What is the dividend yield of Pathfinder Cell Therapy?

The current dividend yield of Pathfinder Cell Therapy is .

When does Pathfinder Cell Therapy pay dividends?

Pathfinder Cell Therapy pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pathfinder Cell Therapy?

Pathfinder Cell Therapy paid dividends every year for the past 0 years.

What is the dividend of Pathfinder Cell Therapy?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pathfinder Cell Therapy located?

Pathfinder Cell Therapy is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pathfinder Cell Therapy kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pathfinder Cell Therapy from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Pathfinder Cell Therapy pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Pathfinder Cell Therapy in the year 2023?

In the year 2023, Pathfinder Cell Therapy distributed 0 USD as dividends.

In which currency does Pathfinder Cell Therapy pay out the dividend?

The dividends of Pathfinder Cell Therapy are distributed in USD.

All fundamentals about Pathfinder Cell Therapy

Our stock analysis for Pathfinder Cell Therapy Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pathfinder Cell Therapy Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.